SLC5A2 and heart failure: Additionally, the empagliflozin group demonstrated notable reductions in rehospitalization rates compared to the group with escalated furosemide dosage, aligning with previous trials highlighting the efficacy of SGLT2 inhibitors in reducing heart failure-related hospitalizations.